Is AVEO's Tivozanib Any Better Than Placebo For The Treatment Of Renal Cell Carcinoma?

Tivozanib is an oral inhibitor of vascular endothelial growth factor (VEGF), and inhibits all three VEGF receptors. AVEO Pharmaceuticals (AVEO) submitted an NDA in September 2012, based on results of the global Phase III TIVO-1 trial, a randomized superiority-designed pivotal trial evaluating the efficacy and safety of tivozanib compared to sorafenib (Nexavar®) in 517 patients with advanced renal cell carcinoma ((RCC)) who had no prior treatment with a systemic therapy, as well as data from 17 clinical studies involving over 1,000 subjects who received tivozanib.03/15/2013
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news